Chong Kun Dang’s CKD-339 Enters Phase 3 in South Korea for Patients Uncontrolled on Monotherapy
CKD-339, an essential hypertension treatment under development by Chong Kun Dang, is advancing into a Phase 3 clinical trial in South Korea.
Search results for "CKD-339"
Global Asset Managers Expand Holdings in South Korean Pharma and Biotech
Major institutional asset managers are steadily increasing their equity stakes in South Korean pharmaceutical and biotechnology companies, drawn by...
Oscotec Ramps Up R&D: What Lies Beyond the Success of Lazertinib?
“It doesn’t end with lazertinib. Keep an eye out for the next candidate in line.” Oscotec is aggressively channeling...
Oscotec to Present Kidney Failure Treatment Candidate at World Congress of Nephrology in Japan
Oscotec announced on the 23rd that it will present animal-model proof-of-concept results for a new drug candidate...
Muscle Loss Linked to Rapid Kidney Decline: Mortality Risk Increases 3.8-Fold
A new long-term study has revealed that the loss of muscle mass is a critical, and often fatal, factor for patients...
The Silent Threat: Why Untreated Hypertension Risks Full-Body Vascular Damage
When diagnosed with hypertension, many patients react with denial, questioning why they have been singled out.
Pharmaceutical Industry Establishes Successive R&BD Subsidiaries... Is Yuhan Corporation Joining?
Yuhan Corporation recently announced plans to establish a specialized subsidiary for 'Research and Business Development...
Oral Obesity Drug Launched in the U.S.… Where is K-Bio Pharmaceutical Now?
Denmark's Novo Nordisk's obesity drug ‘Wegovy Pill (ingredient name Semaglutide)’ has recently been launched in the U. S.
1